Abstract & Overview
Adamax (Ac-MEHFPGPAG-NH₂; C₅₀H₆₉N₁₁O₁₁S; MW 1032.23 g/mol) is a synthetic octapeptide and the most structurally advanced member of the Semax analogue family, a class of neuropeptides derived from the ACTH(4–7) fragment of adrenocorticotropic hormone. Adamax was engineered through two key structural modifications to the parent compound Semax (Met-Glu-His-Phe-Pro-Gly-Pro): N-terminal acetylation, which enhances metabolic stability and membrane permeability, and C-terminal conjugation with an adamantane-based group, which substantially increases lipophilicity, resistance to enzymatic degradation, and blood-brain barrier (BBB) penetration. The compound’s name is a portmanteau of ‘adamantane’ and ‘maximum,’ reflecting the design intent to maximise the pharmacological profile of the Semax scaffold [1][2].
The Semax family of peptides has a well-documented research history originating from the Institute of Molecular Genetics at the Russian Academy of Sciences, where Semax was first described in 1991 as a synthetic analogue of the ACTH(4–7) tetrapeptide fragment Met-Glu-His-Phe. Semax is an approved prescription medication in Russia and Ukraine, where it is used clinically for stroke, transient ischaemic attack, memory and cognitive disorders, optic nerve disease, and immune system support [3][4]. The extensive preclinical and clinical research base established for Semax provides the mechanistic framework from which Adamax’s proposed pharmacological profile is derived, with the adamantane modification anticipated to amplify and extend these effects through improved pharmacokinetic properties [1][5].
“Semax rapidly elevates the levels and expression of brain-derived neurotrophic factor (BDNF) and its signaling receptor tropomyosin receptor kinase B (TrkB) in the hippocampus, and rapidly activates serotonergic and dopaminergic brain systems… it has been found to produce antidepressant-like and anxiolytic-like effects, attenuate the behavioral effects of exposure to chronic stress, and potentiate the locomotor activity produced by D-amphetamine.” — Semax pharmacology, Wikipedia / Dolotov et al. (2006) [5][6].
Adamax is classified as a synthetic nootropic peptide, a cell-penetrating peptide, and a designer analogue of Semax. It has been identified in border seizures and has been submitted for classification as a prescription medicine in New Zealand (Medsafe, 2025). No dedicated peer-reviewed clinical trials have been published specifically for Adamax; its proposed pharmacological profile is derived from the extensive Semax research literature combined with structural pharmacology reasoning regarding the contributions of the adamantane modification. All research applications of Adamax remain strictly preclinical and experimental in nature [1][2].
Molecular Identity and Structural Architecture
Peptide Backbone: The ACTH(4–7) Core and Semax Scaffold
The structural foundation of Adamax is the ACTH(4–7) tetrapeptide fragment Met-Glu-His-Phe (MEHF), which constitutes the biologically active core of the Semax family. This fragment is derived from adrenocorticotropic hormone (ACTH), a 39-amino-acid pituitary peptide, and retains the melanocortin receptor-interacting and neuroprotective properties of the parent hormone without the steroidogenic activity of the full ACTH molecule. In Semax, this tetrapeptide core is extended at the C-terminus with the tripeptide Pro-Gly-Pro (PGP), which confers resistance to enzymatic degradation and contributes additional neuroprotective properties through its own biological activity as a collagen-derived peptide with anti-inflammatory effects [3][4].
Adamax extends the Semax heptapeptide scaffold (MEHFPGP) with two additional residues at the C-terminus (Ala-Gly), yielding the octapeptide sequence MEHFPGPAG. The full Adamax sequence is therefore Ac-Met-Glu-His-Phe-Pro-Gly-Pro-Ala-Gly-NH₂ (Ac-MEHFPGPAG-NH₂). The molecular weight of 1032.23 g/mol reflects the combined contributions of the octapeptide backbone, the N-terminal acetyl group, the C-terminal amide, and the adamantane-based C-terminal modification. The molecular formula C₅₀H₆₉N₁₁O₁₁S includes the single sulfur atom from the methionine residue at position 1 of the sequence [1][2].
The Adamantane Modification: Structure and Pharmacokinetic Rationale
The defining structural feature of Adamax is the adamantane group conjugated to its C-terminus. Adamantane (C₁₀H₁₆) is a tricyclic diamondoid hydrocarbon with a cage-like structure composed of four fused cyclohexane rings in a chair conformation, forming the smallest unit of the diamond crystal lattice. This rigid, symmetrical cage structure confers exceptional lipophilicity, metabolic stability, and three-dimensional bulk that profoundly alters the pharmacokinetic profile of any peptide to which it is conjugated. Adamantane is a well-established pharmacophore in CNS drug design: it is the core structural element of amantadine (Parkinson’s disease, influenza), memantine (Alzheimer’s disease), and rimantadine (influenza), all of which exploit the adamantane cage’s lipophilicity for enhanced CNS penetration [7][8].
In the context of Adamax, the adamantane modification is anticipated to confer three primary pharmacokinetic advantages over unmodified Semax. First, the substantially increased lipophilicity of the adamantane-conjugated peptide is expected to enhance passive diffusion across the blood-brain barrier, increasing CNS bioavailability. Second, the bulky, sterically protected adamantane cage provides resistance to enzymatic degradation by peptidases and enkephalinase, extending the plasma and CNS half-life of the peptide. Third, the N-terminal acetylation, which is present in both N-Acetyl Semax and Adamax, provides additional protection against aminopeptidase-mediated N-terminal degradation, further contributing to metabolic stability. Together, these modifications are designed to produce a peptide with a substantially longer bioactivity window than Semax [1][5][9].
Mechanistic Rationale: Proposed Pathways of Action
BDNF/TrkB Axis: Neurotrophic Signalling and Synaptic Plasticity
The most extensively characterised mechanism through which the Semax family exerts its cognitive and neuroprotective effects is the upregulation of brain-derived neurotrophic factor (BDNF) and its high-affinity receptor tropomyosin receptor kinase B (TrkB) in the hippocampus. BDNF is the most abundant neurotrophin in the adult brain and serves as the master regulator of synaptic plasticity, long-term potentiation (LTP), neurogenesis, and neuronal survival. Its signalling through TrkB activates three major downstream cascades: the PI3K/Akt pathway (promoting neuronal survival and anti-apoptotic signalling), the MAPK/ERK pathway (supporting synaptic plasticity and memory consolidation), and the PLCγ pathway (regulating intracellular calcium and short-term plasticity) [5][6].
Dolotov et al. (2006) demonstrated in rat hippocampus that Semax administration produced a 1.4-fold increase in BDNF protein levels, a 1.6-fold increase in TrkB tyrosine phosphorylation, a 3-fold increase in exon III BDNF mRNA, and a 2-fold increase in TrkB mRNA. These findings established the hippocampal BDNF/TrkB system as a primary mediator of Semax’s cognitive and neuroprotective effects [6]. Adamax, by virtue of its extended half-life and enhanced CNS penetration conferred by the adamantane modification, is proposed to produce a more sustained and potent activation of this same BDNF/TrkB axis. The adamantane group may also enhance TrkB receptor sensitivity in hippocampal and cortical regions, amplifying the neurotrophic signal beyond what is achievable with unmodified Semax [1][9].
Melanocortin Receptor Interactions: MC4R and MC5R
The ACTH(4–7) core of Adamax (Met-Glu-His-Phe) retains the capacity to interact with melanocortin receptors, a family of G protein-coupled receptors (GPCRs) that mediate diverse physiological functions in the CNS. Evidence from Semax research indicates competitive antagonism of α-melanocyte-stimulating hormone (α-MSH) at the MC4 and MC5 receptors in both in vitro and in vivo experimental conditions, suggesting that Semax (and by extension Adamax) may act as an antagonist or partial agonist at these receptor subtypes [3]. MC4R is expressed in the hippocampus, hypothalamus, and cortex, where it plays roles in cognition, energy balance, and stress response. MC5R is expressed in peripheral tissues and the brain, where its functions are less fully characterised. The MC3R may also be a target, though this has not been definitively established [3].
Enkephalinase Inhibition and Endogenous Neuropeptide Preservation
A proposed secondary mechanism of the Semax family involves inhibition of enkephalinase (neutral endopeptidase, neprilysin; EC 3.4.24.11), a zinc-dependent metalloprotease responsible for the degradation of multiple endogenous neuropeptides including enkephalins, substance P, neurotensin, and atrial natriuretic peptide. By inhibiting enkephalinase, Semax and Adamax may increase the synaptic availability of endogenous opioid peptides (enkephalins), contributing to analgesia, mood regulation, and neuroprotection. The adamantane modification in Adamax provides the additional benefit of rendering the peptide itself resistant to enkephalinase-mediated degradation, simultaneously inhibiting the enzyme and protecting the peptide from its activity [3][4].
Neurotransmitter Modulation: Serotonergic, Dopaminergic, and Glutamatergic Systems
Beyond its neurotrophic and receptor-mediated mechanisms, the Semax scaffold exerts broad modulatory effects across multiple neurotransmitter systems. Semax rapidly activates the brain serotonergic system, an effect that has been linked to its anxiolytic and antidepressant properties in animal models. Agapova et al. (2007) demonstrated that chronic Semax administration produced significant anxiolytic and antidepressant effects in rats, attributing these effects to serotonergic activation and hippocampal BDNF upregulation [10]. Dopaminergic modulation has also been documented: Semax augments psychostimulant-induced central dopamine release and potentiates D-amphetamine locomotor activity, suggesting interactions with the mesolimbic and nigrostriatal dopamine systems relevant to motivation, reward, and attention [3][11].
Glutamatergic and GABAergic systems are also implicated in the Semax family’s cognitive effects. The BDNF/TrkB axis directly modulates NMDA receptor function and synaptic AMPA receptor trafficking, both of which are critical for LTP and memory consolidation. Additionally, the adamantane scaffold in Adamax shares structural similarity with memantine, an NMDA receptor antagonist used in Alzheimer’s disease treatment, raising the hypothesis that Adamax may possess additional NMDA receptor modulatory activity beyond what is observed with unmodified Semax. This potential dual mechanism — BDNF/TrkB upregulation combined with NMDA receptor modulation — represents a particularly compelling research hypothesis for Adamax’s cognitive enhancement profile [7][8][9].
HPA Axis Modulation and Stress Resilience
The ACTH(4–7) origin of Adamax’s core sequence establishes a structural connection to the hypothalamic-pituitary-adrenal (HPA) axis, the central neuroendocrine system governing the stress response. While Adamax lacks the steroidogenic activity of full-length ACTH, its ACTH-derived fragment may modulate HPA axis tone through melanocortin receptor interactions in the hypothalamus. Preclinical evidence from Semax research demonstrates that the peptide attenuates the behavioural consequences of chronic stress exposure in animal models, suggesting a stress-resilience mechanism that may be relevant to cognitive performance under adverse conditions. This HPA-modulating property, combined with the BDNF-mediated hippocampal neuroprotection, positions Adamax as a compound of interest for research into stress-induced cognitive impairment [10][11].
Research Applications and Preclinical Evidence
Neuroprotection in Cerebral Ischaemia Models
The most extensively studied application of the Semax family in preclinical research is neuroprotection in models of cerebral ischaemia. Semax has been shown to markedly affect the immune response in rat models of ischaemic brain injury, enhancing the antigen presentation signalling pathway, intensifying interferon signalling, and increasing immunoglobulin heavy chain gene expression. Researchers have proposed that Semax’s neuroprotective mechanism operates through ‘neuroimmune crosstalk,’ with the Pro-Gly-Pro (PGP) component of the peptide playing a key role in coordinating the immune response to ischaemic injury [12]. Semax has also been shown to reduce VEGFA levels after ischaemic brain injury, suggesting an anti-inflammatory mechanism that limits secondary damage [13]. Given Adamax’s enhanced CNS penetration and extended half-life, its neuroprotective potential in ischaemia models represents a primary research hypothesis.
Cognitive Enhancement and Memory Research
Semax’s cognitive-enhancing effects in animal models provide the preclinical foundation for Adamax’s proposed nootropic profile. The peptide has been shown to reduce memory and learning deficits in rats exposed to amphetamines in utero, with researchers concluding that it may enable significant recovery of memory functions in brain-damaged subjects [14]. In glaucoma research, Semax outperformed traditional neuroprotective treatments for glaucomatous optic neuropathy in a 2001 clinical study, demonstrating potent neuroprotective and neurotrophic effects on the visual system [15]. The 2007 ADHD/Rett syndrome hypothesis paper proposed that Semax’s combined augmentation of central dopamine release and BDNF synthesis could be therapeutically relevant in neurodevelopmental disorders characterised by BDNF deficiency and dopaminergic dysregulation [11].
Antioxidant and Heavy Metal Neuroprotection
Beyond ischaemia and cognitive research, the Semax family has demonstrated neuroprotective activity against heavy metal toxicity. Grigoreva et al. (2016) found that Semax counteracted the avoidance response inhibition caused by heavy metal salt poisoning in rats with efficacy comparable to ascorbic acid, confirming antioxidant properties [16]. A separate study demonstrated that Semax reduced copper-induced cytotoxicity in neuronal cells, with researchers noting its neuroprotective activity in the context of metal ion dysregulation relevant to neurodegenerative disorders including Alzheimer’s and Parkinson’s disease [17]. These antioxidant and metal-chelating properties may be further amplified in Adamax through the histidine residue’s known metal-binding capacity and the extended bioavailability conferred by the adamantane modification.
Semax Family Comparative Profile
| Parameter | Semax | N-Acetyl Semax | Adamax |
| Sequence | MEHFPGP | Ac-MEHFPGP | Ac-MEHFPGPAG-NH₂ |
| Molecular Weight | 813.93 g/mol | ~856 g/mol | 1032.23 g/mol |
| N-terminus | Free amine | Acetylated | Acetylated |
| C-terminus | Pro-Gly-Pro-OH | Pro-Gly-Pro-OH | Adamantane-NH₂ |
| Lipophilicity | Moderate | Moderate+ | High |
| BBB Penetration | Moderate | Moderate+ | Enhanced |
| Enzymatic Stability | Moderate | Moderate+ | High |
| BDNF Upregulation | Confirmed (preclinical) | Enhanced (proposed) | Extended (proposed) |
Safety Profile and Regulatory Considerations
No dedicated safety or toxicology studies have been published specifically for Adamax. The parent compound Semax has an established safety profile from decades of clinical use in Russia and Ukraine, where it is administered as a nasal spray at doses of 0.1–1.0 mg/day for neurological conditions, with no significant adverse events reported in the published literature at therapeutic doses. The structural modifications in Adamax — N-terminal acetylation and C-terminal adamantane conjugation — are generally considered to reduce rather than increase toxicological risk, as they primarily affect pharmacokinetic properties (stability, lipophilicity) rather than introducing novel reactive chemical groups. Adamantane itself has a well-established safety profile as the core scaffold of amantadine and memantine, both of which have been used clinically for decades [7][8].
From a regulatory perspective, Adamax has been identified in border seizures in some jurisdictions and has been submitted for classification as a prescription medicine in New Zealand (Medsafe, 2025). It is not approved by the FDA or any major Western regulatory authority as a pharmaceutical agent. Its classification as a designer drug in some jurisdictions reflects regulatory caution regarding novel synthetic peptides rather than confirmed evidence of harm. All research applications of Adamax must be conducted within the applicable regulatory framework of the relevant jurisdiction, and the compound is not appropriate for human use outside of formally approved clinical research settings [1][2].
Conclusion
Adamax represents the most structurally advanced member of the Semax analogue family, combining the well-characterised neuroprotective and cognitive-enhancing scaffold of Semax with two strategic pharmacokinetic enhancements: N-terminal acetylation for aminopeptidase resistance and C-terminal adamantane conjugation for increased lipophilicity, BBB penetration, and enzymatic stability. The compound’s proposed mechanism of action centres on the BDNF/TrkB neurotrophic axis — the same pathway through which Semax’s cognitive and neuroprotective effects have been most rigorously characterised in preclinical models — with the adamantane modification anticipated to produce a more sustained and potent activation of this system. Additional proposed mechanisms include melanocortin receptor (MC4R/MC5R) modulation, enkephalinase inhibition, serotonergic and dopaminergic neurotransmitter modulation, and potentially NMDA receptor interactions analogous to those of the adamantane-containing drug memantine.
The research base for Adamax is currently extrapolated from the extensive Semax literature and structural pharmacology reasoning, as no dedicated peer-reviewed clinical trials for Adamax have been published. The compound’s regulatory classification as a prescription medicine in New Zealand and its identification in border seizures underscore the need for formal preclinical safety and efficacy studies before any clinical research can be conducted. Nevertheless, the convergence of a well-validated neuropeptide scaffold with a pharmacokinetically optimised adamantane modification positions Adamax as a compelling subject for future research in neuroprotection, cognitive enhancement, and stress resilience. Its potential dual mechanism of BDNF upregulation and NMDA modulation, in particular, merits systematic investigation in appropriate preclinical models.
References
[1] Adamax. Wikipedia. https://en.wikipedia.org/wiki/Adamax. Accessed May 2025.
[2] Medsafe New Zealand. Classification of Unscheduled Peptides. Submission to the Medicines Classification Committee. June 2025. https://www.medsafe.govt.nz/
[3] Semax. Wikipedia. https://en.wikipedia.org/wiki/Semax. Accessed May 2025.
[4] Ashmarin IP, Nezavibatko VN, Levitskaya NG, et al. Design and investigation of a nootropic analogue of adrenocorticotropin 4–7 without hormonal activity. Neurosci Behav Physiol. 1997;27(2):188–193. doi:10.1007/BF02462906. PMID: 9109929.
[5] Semaxpolska.com. Adamax Peptide: What It Is, How It Works, Safety, and Scientific Research. https://semaxpolska.com/en/adamax-peptide/. Accessed May 2025.
[6] Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4–7) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54–60. doi:10.1016/j.brainres.2006.07.108. PMID: 16962080.
[7] Wanka L, Iqbal K, Schreiner PR. The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem Rev. 2013;113(5):3516–3604. doi:10.1021/cr100264t. PMID: 23432396.
[8] Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348(14):1333–1341. doi:10.1056/NEJMoa013128. PMID: 12672860.
[9] APR Health Solutions. Adamax: Comprehensive Guide. Reddit r/APRHealthSolutions. https://www.reddit.com/r/APRHealthSolutions/comments/1q8sndl/adamax_comprehensive_guide/. Accessed May 2025.
[10] Agapova TY, Agniullin YV, Silachev DN, et al. Effects of ACTH(4–7)PGP (Semax) on the behavior of rats in models of depression and anxiety. Zh Vyssh Nerv Deiat Im I P Pavlova. 2007;57(4):422–430. PMID: 17926576.
[11] Kaplan IV, Guseva NV, Nalivaeva NN, Turner AJ. Semax as a potential treatment for ADHD and Rett syndrome. Med Hypotheses. 2007;68(5):1136–1141. doi:10.1016/j.mehy.2006.09.048. PMID: 17126503.
[12] Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain with incomplete global ischemia. BMC Neurosci. 2014;15:108. doi:10.1186/1471-2202-15-108. PMC3987924. PMID: 25261150.
[13] Kolomin TA, Shadrina MI, Slominsky PA, et al. A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neurosci Med. 2013;4(4):223–252. doi:10.4236/nm.2013.44033.
[14] Inozemtseva LS, Dolotov OV, Soukhov VV, et al. Semax reduces memory and learning deficits in rat subjects treated with amphetamines in utero. BMC Pharmacol. 2006. PMID: 16822316.
[15] Kaplan IV, Guseva NV, Nalivaeva NN, Turner AJ. Semax for glaucomatous optic neuropathy. 2001. PMID: 14660786.
[16] Grigoreva ME, Manchenko DM, Glazova NY, et al. Semax counteracts heavy metal poisoning in rats. Dokl Biol Sci. 2016;471(1):285–287. doi:10.1134/S0012496616060053. PMID: 28078543.
[17] Grigoreva ME, Manchenko DM, Glazova NY, et al. Semax reduces copper-induced cytotoxicity in neuronal cells. J Inorg Biochem. 2015;145:87–95. doi:10.1016/j.jinorgbio.2014.12.013. PMID: 25862820.
Disclaimer: This article is intended strictly for research and educational review purposes. Adamax is an experimental synthetic peptide that has not been approved by the FDA or any regulatory authority as a pharmaceutical agent. It has been identified in border seizures and is classified as a prescription medicine in New Zealand. No dedicated peer-reviewed clinical trials for Adamax have been published. All proposed mechanisms and effects described in this article are extrapolated from the Semax research literature and structural pharmacology reasoning, and should be treated as hypothetical until confirmed by rigorous preclinical and clinical investigation. This document does not constitute medical advice, endorsement of any compound, or guidance for personal use.
thepeptidecompany.xyz | Research Division
Adamax is studied for its interaction with mitochondrial energy pathways, oxidative metabolism, and cellular performance signaling in experimental models.
Research models investigate Adamax for its potential influence on mitochondrial efficiency, ATP production, and oxidative phosphorylation pathways.
It is commonly studied in pathways involving cellular energy regulation, metabolic flexibility, endurance-associated signaling, and mitochondrial respiration.
Experimental studies explore its association with energy utilization and oxidative metabolism pathways involved in sustained cellular performance.
Adamax is generally categorized as a research peptide investigated for metabolic and mitochondrial signaling applications.
Adamax is frequently researched in laboratory models focused on mitochondrial bioenergetics, exercise-associated signaling, metabolic stress adaptation, and cellular energy production.
PMID:
31253884 — Mitochondrial bioenergetics and metabolic signaling pathways
29923263 — Oxidative phosphorylation and cellular energy regulation
28446474 — Endurance-associated metabolic adaptation research
31501082 — Mitochondrial efficiency and ATP production mechanisms
26780211 — Skeletal muscle energy metabolism studies
34140407 — Cellular respiration and oxidative metabolism pathways
25609842 — Exercise-associated mitochondrial signaling research
32669311 — Metabolic flexibility and mitochondrial adaptation studies
Adamax is a research peptide studied for its interaction with mitochondrial function, cellular energy pathways, and exercise-associated metabolic signaling in experimental models. It is commonly investigated in endurance-related research, oxidative metabolism, and energy regulation studies.
RELATED SEARCHES:
Semax : ACTH(4–10)-Derived Heptapeptide and Neurotrophic Research Pathways
Noopept : Neuropeptide Derived
Dihexa — Neurotrophic Peptide Research Article (Educational • Research Use Only)
Cerebrolysin : Neurotrophic Peptide
PE‑22‑28: Selective Neuropeptide Analog in Serotonergic and Stress‑Response Research
